Logo image of ANTX

AN2 THERAPEUTICS INC (ANTX) Stock Fundamental Analysis

NASDAQ:ANTX - Nasdaq - US0373261058 - Common Stock - Currency: USD

1.25  0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ANTX. ANTX was compared to 198 industry peers in the Pharmaceuticals industry. ANTX has a great financial health rating, but its profitability evaluates not so good. ANTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ANTX had negative earnings in the past year.
ANTX had a negative operating cash flow in the past year.
In the past 5 years ANTX always reported negative net income.
ANTX had a negative operating cash flow in each of the past 5 years.
ANTX Yearly Net Income VS EBIT VS OCF VS FCFANTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -55.73%, ANTX is not doing good in the industry: 63.13% of the companies in the same industry are doing better.
ANTX has a Return On Equity (-62.70%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -55.73%
ROE -62.7%
ROIC N/A
ROA(3y)-48.03%
ROA(5y)-106.84%
ROE(3y)-53.15%
ROE(5y)-145.1%
ROIC(3y)N/A
ROIC(5y)N/A
ANTX Yearly ROA, ROE, ROICANTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANTX Yearly Profit, Operating, Gross MarginsANTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANTX has more shares outstanding
ANTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ANTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANTX Yearly Shares OutstandingANTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ANTX Yearly Total Debt VS Total AssetsANTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

ANTX has an Altman-Z score of -1.89. This is a bad value and indicates that ANTX is not financially healthy and even has some risk of bankruptcy.
ANTX has a Altman-Z score (-1.89) which is comparable to the rest of the industry.
ANTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.89
ROIC/WACCN/A
WACCN/A
ANTX Yearly LT Debt VS Equity VS FCFANTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

ANTX has a Current Ratio of 8.43. This indicates that ANTX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.43, ANTX is doing good in the industry, outperforming 79.80% of the companies in the same industry.
A Quick Ratio of 8.43 indicates that ANTX has no problem at all paying its short term obligations.
The Quick ratio of ANTX (8.43) is better than 80.30% of its industry peers.
Industry RankSector Rank
Current Ratio 8.43
Quick Ratio 8.43
ANTX Yearly Current Assets VS Current LiabilitesANTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

ANTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.84%, which is quite impressive.
EPS 1Y (TTM)41.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ANTX will show a small growth in Earnings Per Share. The EPS will grow by 2.91% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.9%
EPS Next 2Y11.38%
EPS Next 3Y11.45%
EPS Next 5Y2.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANTX Yearly EPS VS EstimatesANTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANTX Price Earnings VS Forward Price EarningsANTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANTX Per share dataANTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.38%
EPS Next 3Y11.45%

More info and screens

0

5. Dividend

5.1 Amount

ANTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AN2 THERAPEUTICS INC

NASDAQ:ANTX (4/28/2025, 2:05:05 PM)

1.25

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-25 2025-03-25/amc
Earnings (Next)05-07 2025-05-07
Inst Owners46.28%
Inst Owner Change-0.44%
Ins Owners9.72%
Ins Owner Change15.38%
Market Cap37.63M
Analysts50
Price Target2.72 (117.6%)
Short Float %0.27%
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.38%
Min EPS beat(2)3.88%
Max EPS beat(2)10.87%
EPS beat(4)4
Avg EPS beat(4)11.75%
Min EPS beat(4)3.88%
Max EPS beat(4)20.68%
EPS beat(8)6
Avg EPS beat(8)7.93%
EPS beat(12)8
Avg EPS beat(12)-33.24%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-74.19%
EPS NQ rev (1m)1.36%
EPS NQ rev (3m)-3.9%
EPS NY rev (1m)0.21%
EPS NY rev (3m)0.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.46
P/tB 0.46
EV/EBITDA N/A
EPS(TTM)-1.64
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-1.64
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS0
BVpS2.72
TBVpS2.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.73%
ROE -62.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.03%
ROA(5y)-106.84%
ROE(3y)-53.15%
ROE(5y)-145.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.43
Quick Ratio 8.43
Altman-Z -1.89
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.14%
EPS Next Y33.9%
EPS Next 2Y11.38%
EPS Next 3Y11.45%
EPS Next 5Y2.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.56%
OCF growth 3YN/A
OCF growth 5YN/A